Aluminium overload influences cognitive function in patients on dialysis.
Kambova
L
L
Ionova
D
D
Kirijakov
Z
Z
D000328:Adult; D000535:Aluminum / Q000009:adverse effects*; D001927:Brain Diseases / Q000139:chemically induced / Q000188:drug therapy; D002614:Chelating Agents; D003071:Cognition / Q000187:drug effects*; D003676:Deferoxamine / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009942:Organometallic Compounds / Q000627:therapeutic use; D006435:Renal Dialysis; D014511:Uremia / Q000628:therapy
D002614:Chelating Agents; D009942:Organometallic Compounds; C049544:aluminoxamine; D000535:Aluminum; D003676:Deferoxamine